No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

SafeSource Direct Receives FDA Clearance for American-Made PPE

Editor: What To Know

  • Created as a joint venture between Ochsner and Trax Development during the COVID-19 pandemic, SafeSource Direct is the only PPE manufacturer that is U.
  • As the company expands its capacity over the coming months, it will be among the largest manufacturers of chemo-rated nitrile exam gloves in America- if not the largest.
  • “Throughout the pandemic we had to innovate, and as a result, we believe we're better prepared for the next public health crisis or global supply shortage,” said Aimee Quirk, CEO, Ochsner Ventures, Ochsner Health.

SafeSource Direct, LLC, the maker of high-quality, American-made personal protective equipment (PPE), announced today that its chemo-rated nitrile exam gloves have received FDA 510(k) clearance. The determination follows extensive testing and clears the way for the gloves to be used in healthcare.

“This marks a tremendous step toward U.S. supply resilience as healthcare providers look to mitigate risks in sourcing critical supplies,” said Justin Hollingsworth, CEO, SafeSource Direct. “While COVID-era shortages and substandard products may seem like things of the past, the risk that our nation’s healthcare providers find themselves in a similar situation remains very real. That’s why we’re offering a solution that sidesteps the supply interruptions and lack of quality control that come with dependence on foreign manufacturers.”

Hollingsworth says SafeSource Direct is ready to meet the nation’s demand to keep people safe. With two state-of-the-art facilities in Broussard, Louisiana, it has multiple operational production lines capable of manufacturing 108,000 gloves per hour. The company aims to have a dozen lines operational by January 2024 capable of producing over 2 billion gloves annually with additional manufacturing capacity available on-site. As the company expands its capacity over the coming months, it will be among the largest manufacturers of chemo-rated nitrile exam gloves in America- if not the largest.

In addition to gloves, SafeSource Direct produces Level 1 and 3 surgical ear loop and surgical tie masks and standard three-ply Level 1 and 3 procedure masks, which received FDA 510(k) clearance in May. It also makes shoe covers and will soon be making N95 respirators, hair bouffant covers, and isolation gowns.

With SafeSource Direct’s rapid expansion has come more than 850 American jobs, with 2,200 total expected over the coming months. The company is also planning to become completely vertically integrated by sourcing raw materials in a nearby facility in Louisiana.

“One hundred percent American owned, American operated, and on American soil– we’re uniquely positioned to help solve America’s PPE supply challenges,” Hollingsworth said.

SafeSource Direct also stands out through its partnership with the Gulf South’s largest health system, Ochsner Health. Created as a joint venture between Ochsner and Trax Development during the COVID-19 pandemic, SafeSource Direct is the only PPE manufacturer that is U.S. provider-owned with U.S. provider-owned quality control.

“Throughout the pandemic we had to innovate, and as a result, we believe we’re better prepared for the next public health crisis or global supply shortage,” said Aimee Quirk, CEO, Ochsner Ventures, Ochsner Health. “This is a long-term, sustainable solution to mitigate risks inherent in the global supply chain.”

“Since COVID, we’ve seen the spread of additional dangerous infectious diseases, inflation, and numerous global conflicts. These types of situations will continue to emerge and disrupt supply,” said Regine Villain, System Vice President of Supply Chain Network and Chief Supply Chain Officer, Ochsner Health. “That’s why we decided to take matters into our own hands with an onshore company that can meet our nation’s PPE supply needs.”

She said purchasing from SafeSource Direct also aligns with the healthcare system’s environmental, social, and governance (ESG) priorities.

“Buying from SafeSource Direct eliminates the carbon emissions associated with shipping containers around the world, and it ensures that our products are not only high quality but also manufactured ethically,” said Villain.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy